|
|
|
| Efficacy of Different Doses of Perindopril in the Treatment of Patients with Ischemic Heart Failure and its Effects on Cardiac Function and Serum Indicators |
| LI Furong, YU Weiren, PI Shufang |
| Department of Internal Medicine, Xikang Hospital, Tianjin 300000 |
|
|
|
|
Abstract 【Objective】To investigate the efficacy of different doses of perindopril in the treatment of patients with ischemic heart failure and its effects on cardiac function and serum indicators. 【Methods】The clinical data of 100 patients with ischemic heart failure diagnosed and treated at Tianjin Jinnan District Xikang Hospital from April 2019 to April 2022 were retrospectively analyzed. According to the dosage of perindopril, the patients were divided into a high-dose group (treated with a high dose of perindopril, n=52) and a low-dose group (treated with a low dose of perindopril, n=48). The treatment efficacy, incidence of adverse reactions, serum levels of neutrophil gelatinase-associated lipocalin (NGAL) and N-terminal pro-brain natriuretic peptide (NT-proBNP), left ventricular ejection fraction (LVEF), left ventricular end-systolic diameter (LVESD), and left ventricular end-diastolic diameter (LVEDD) were compared between the two groups before and after treatment. 【Results】The total effective rate in the high-dose group was 94.23%, significantly higher than that in the low-dose group (79.17%), and the difference was statistically significant (P<0.05). After treatment, the serum levels of NGAL and NT-proBNP in both groups were significantly lower than those before treatment, and the levels in the high-dose group were lower than those in the low-dose group (P<0.05). After treatment, the LVEF in both groups was significantly higher than that before treatment, and it was higher in the high-dose group than in the low-dose group; the LVESD and LVEDD were significantly shorter than those before treatment, and they were shorter in the high-dose group than in the low-dose group (P<0.05). There was no statistically significant difference in the total incidence of adverse reactions between the two groups (P>0.05). 【Conclusion】 High-dose perindopril is more effective in treating patients with ischemic heart failure, significantly improving serum levels of NGAL and NT-proBNP, as well as cardiac function.
|
|
Received: 14 May 2024
|
|
|
|
|
|
[1] 陆心怡, 郑旭辉, 廖深根,等. 营养控制状态评分与急性心力衰竭患者长期预后的相关性分析[J].中华心血管病杂志, 2021, 49(12):1220-1226.
[2] 王飞飞, 潘立栋. 通心络胶囊联合美托洛尔对老年缺血性心肌病合并心力衰竭患者的临床疗效及安全性观察[J].贵州医药, 2022, 46(4):616-618.
[3] 许韩波, 黄燕洪. 培哚普利联合左卡尼汀对心力衰竭患者运动耐量的影响[J].中华老年多器官疾病杂志, 2021, 20(5):349.
[4] 周巍, 王燕华, 张帅,等. 环磷腺苷葡胺联合培哚普利治疗对心力衰竭患者心功能改善作用[J].心脑血管病防治, 2020, 20(1):113-115.
[5] 中华医学会心血管病学分会心力衰竭学组, 中国医师协会心力衰竭专业委员会, 中华心血管病杂志编辑委员会. 中国心力衰竭诊断和治疗指南2018[J].中华心血管病杂志, 2018, 46(10):760-789.
[6] 王春蕾, 张丹, 王桂东. 曲美他嗪联合注射用重组人脑利钠肽治疗慢性缺血性心力衰竭的效果[J].中国医药导报, 2020, 17(20):58-61.
[7] 夏勇, 张建卿, 王少霞,等. 沙库巴曲缬沙坦联合琥珀酸美托洛尔缓释片治疗冠状动脉粥样硬化性心脏病并慢性心力衰竭的效果观察[J].首都医科大学学报, 2020, 41(1):113-118.
[8] 龙骁, 陈然, 程春,等. AMI后心力衰竭应用不同剂量培哚普利的疗效及对NT-proBNP及心肌能量消耗的影响[J].中国临床研究, 2017, 30(6):740-743.
[9] 杨玉杰, 戴骏, 何庆芳,等. 中性粒细胞明胶酶相关脂质运载蛋白对高血压病合并颈动脉粥样硬化的诊断价值[J].心脑血管病防治, 2022, 22(1):39-42.
[10] ALLAWI A A D , KAHDEM A A , NADA S Z , et al. Neutrophil gelatinase associated lipocalin (NGAL) in early detection of nephropathy in type 2 diabetic Iraqi patients[J].J Faculty Med Baghdad,2017, 59(1):45-47.
[11] 温红静, 卢雄豪, 余光勇,等. 缺血性心力衰竭患者尿NGAL水平与血清 pro-BNP相关性及诊断价值分析[J].河北医学, 2019, 25(5):711-716.
[12] 方叶飞. 缺血性心力衰竭患者尿中性粒细胞明胶酶相关脂质运载蛋白水平与血清N-末端脑钠肽前体相关性及诊断价值分析[J].中国药物与临床, 2019, 19(19):3323-3325.
[13] 张晓华. ACEI联合利尿剂对老年原发性高血压伴心力衰竭病人心脏功能及脑钠肽、C反应蛋白的影响[J].中西医结合心脑血管病杂志, 2019, 17(16):2507-2510.
[14] 王美力, 蔡海滨, 李东升. 培哚普利联合卡维地洛对老年充血性心力衰竭患者心功能及炎性指标的影响[J].岭南心血管病杂志, 2021, 27(1):67-71.
[15] 杨静, 高日扬, 黎云,等. 大剂量培哚普利动员内皮祖细胞对心肌梗死后心力衰竭患者心功能的影响[J].内科急危重症杂志, 2020, 26(1):47-49. |
|
|
|
2025, Vol. 42 
